# FDA Panel Backs Donanemab: New Hope for Early Alzheimer’s Treatment

- Link: https://www.widthness.com/fda-panel-backs-donanemab-new-hope-for-early-alzheimers-treatment/
- Published: 2024-06-11T10:00:10-05:00
- Author: Curated by Theresa Wysocki

Image caption: By the end of the trial, 60% of patients were able to effectively stop Donanemab treatment. Image credit: Neuroscience News. Article by Neuroscience News Communications. Neuroscience News – June 10, 2024. Summary: An independent panel has recommended that Eli Lilly’s Alzheimer’s drug, Donanemab, be approved by the FDA. The drug has shown promise in slowing early-stage Alzheimer’s despite risks like brain swelling. This recommendation follows a prior FDA rejection due to insufficient data. If approved, Donanemab could revolutionize Alzheimer’s treatment, offering new hope for patients and their families. […] Click here to view original web page at neurosciencenews.com Related articles: FDA panel makes the call on much-anticipated Alzheimer’s drug donanemab – USA Today FDA Panel Unanimously Recommends Eli Lilly’s Alzheimer’s Drug – Forbes FDA advisors strongly back new Alzheimer’s drug, despite risks and limitations – NPR